ClearPoint Neuro Inc. (CLPT)
NASDAQ (CM) NASDAQ (CM) Primary 
ClearPoint Neuro: Regulatory Momentum Strengthens The Long-Term Investment Case
ClearPoint Neuro's second quarter results were poor across the board, with drug delivery disposables an area of particular weakness. Delays in the ramping of preclinical services at ClearPoint's new facility have also contributed to reduced expectations for 2026. There is now regulatory clarity, though, meaning a revenue inflection as AMT-130 is commercialized is now highly likely in 2027/2028.
ClearPoint Neuro, Inc. (CLPT) Q2 2026 Earnings Call Transcript
ClearPoint Neuro, Inc. (CLPT) Q2 2026 Earnings Call Transcript
ClearPoint Neuro (CLPT) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for ClearPoint Neuro (CLPT) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Misses Revenue Estimates
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.21 per share a year ago.
ClearPoint Neuro Q2 Earnings Call Highlights
ClearPoint Neuro NASDAQ: CLPT reported second-quarter 2026 revenue growth while outlining a shift in investment priorities toward clinical capacity, preclinical laboratory services and technologies intended to support commercial-scale neuro drug delivery.
ClearPoint Neuro (CLPT) Surges 26.0%: Is This an Indication of Further Gains?
ClearPoint Neuro (CLPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Compared to Estimates, ClearPoint Neuro (CLPT) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for ClearPoint Neuro (CLPT) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
ClearPoint Neuro, Inc. (CLPT) Reports Q1 Loss, Lags Revenue Estimates
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.22 per share a year ago.
ClearPoint Neuro Q1 Earnings Call Highlights
ClearPoint Neuro NASDAQ: CLPT reported record first-quarter 2026 revenue and reaffirmed its full-year outlook, as management highlighted growth in its legacy neurosurgical device business and early contributions from the recently acquired IRRAflow product line.
ClearPoint Neuro: Temporary Headwinds Don't Change The Long-Term Outlook
ClearPoint's stock has come under significant pressure in recent months following weaker 2026 revenue guidance and further regulatory uncertainty. Despite near-term headwinds, a step change in revenue remains likely as partner therapies are commercialized over the next few years. Independent of this, ClearPoint's forward revenue multiple looks increasingly reasonable given the company's strong competitive positioning and solid growth.
ClearPoint Neuro, Inc. (CLPT) Q4 2025 Earnings Call Transcript
ClearPoint Neuro, Inc. (CLPT) Q4 2025 Earnings Call Transcript
ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Tops Revenue Estimates
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.2 per share a year ago.
